NCT06192563 - A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Dermatitis Atopic

Interventions

DRUG

Dupilumab

Subcutaneous injection, standard of care as prescribed by treating physician (no investigational drug provided)

Trial Locations (9)

RECRUITING

Investigational Site Number: 001, Milan

RECRUITING

Investigational Site Number: 006, Brescia

RECRUITING

Investigational Site Number: 014, Verona

RECRUITING

Investigational Site Number: 002, Bologna

RECRUITING

Investigational Site Number: 004, Florence

RECRUITING

Investigational Site Number: 010, Napoli

RECRUITING

Investigational Site Number: 011, Napoli

RECRUITING

Investigational Site Number: 005, Roma

RECRUITING

Investigational Site Number: 009, Roma